Alto Neuroscience Inc., a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders, is set to participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. The company's management team will engage in a fireside chat and hold one-on-one investor meetings, with their presentation scheduled for June 5, 2025, at 2:00 pm ET at the New York Marriott Marquis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.